Analyst Price Targets — NUVL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 12:25 pm | — | Truist Financial | $140.00 | $105.88 | TheFly | Nuvalent initiated with a Buy at Truist |
| November 17, 2025 6:25 pm | Etzer Darout | Barclays | $152.00 | $108.00 | TheFly | Nuvalent price target raised to $152 from $112 at Barclays |
| November 17, 2025 4:23 pm | — | Leerink Partners | $149.00 | $110.56 | TheFly | Nuvalent price target raised to $149 from $140 at Leerink |
| November 17, 2025 1:48 pm | — | H.C. Wainwright | $155.00 | $110.60 | TheFly | Nuvalent price target raised to $155 from $130 at H.C. Wainwright |
| November 12, 2025 11:36 am | — | Canaccord Genuity | $126.00 | $96.16 | TheFly | Canaccord starts 'best-in-class' Nuvalent with Buy rating |
| October 31, 2025 1:26 pm | — | Goldman Sachs | $120.00 | $98.17 | TheFly | Nuvalent price target raised to $120 from $105 at Goldman Sachs |
| October 31, 2025 10:03 am | David Dai | UBS | $132.00 | $98.17 | StreetInsider | Nuvalent (NUVL) PT Raised to $132 at UBS |
| October 27, 2025 10:55 am | Kelsey Goodwin | Piper Sandler | $128.00 | $93.39 | TheFly | Nuvalent price target raised to $128 from $112 at Piper Sandler |
| October 15, 2025 1:27 pm | Josh Schimmer | Cantor Fitzgerald | $135.00 | $89.35 | TheFly | Nuvalent initiated with an Overweight at Cantor Fitzgerald |
| September 3, 2025 8:26 pm | — | Guggenheim | $122.00 | $79.54 | TheFly | Nuvalent assumed with a Buy at Guggenheim |
Latest News for NUVL
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in Nuvalent (NUVL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential label expansion of zidesamtinib in TKI-naïve advanced…
Commodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated trade size was $83.81 million based on quarterly average pricing. Meanwhile, the quarter-end position value dropped by $65.75 million, reflecting both share sales and stock price movement.
Nuvalent (NASDAQ: NUVL) executives highlighted ongoing regulatory milestones for the company's lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positioning during a conference fireside chat. Company focus and lead programs Chief Executive Officer Jim Porter described Nuvalent as a company built around deep chemistry and structure-based drug design expertise, with an…
CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVL.
U.S. House Trading
No House trades found for NUVL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.